19.69

10.12% 1.81

Novocure Ltd (NVCR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt NVCR? Forum Prognose

Schlusskurs vom Vortag:

$17.88

Offen:

$18.29

24-Stunden-Volumen:

1.07M

Relative Volume:

1.05

Marktkapitalisierung:

$1.93B

Einnahmen:

$577.74M

Nettoeinkommen (Verlust:

$-149.78M

KGV:

-10.59

EPS:

-1.86

Netto-Cashflow:

$-78.21M

1W Leistung:

+16.79%

1M Leistung:

+17.62%

6M Leistung:

-14.95%

1J Leistung:

+65.32%

1-Tages-Spanne:

$18.00

$19.77

1-Wochen-Bereich:

$16.30

$19.77

52-Wochen-Spanne:

$11.29

$24.73

Novocure Ltd Stock (NVCR) Company Profile

Firmenname

Novocure Ltd

Sektor

Healthcare (1200)

Branche

Medical Devices (153)

Telefon

44 (0)15 3475 6700

Adresse

NO. 4 THE FORUM, ST. HELIER

Mitarbeiter

1,453

Twitter

@novocure

Nächster Verdiensttermin

2024-10-30

Neueste SEC-Einreichungen

NVCR's Discussions on Twitter

Vergleichen Sie NVCR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NVCR Novocure Ltd	19.69	1.93B	577.74M	-149.78M	-78.21M	-1.86
ABT Abbott Laboratories	118.95	208.18B	41.22B	5.77B	6.49B	2.94
SYK Stryker Corp	388.14	148.70B	21.97B	3.59B	3.21B	6.74
BSX Boston Scientific Corp	90.75	133.32B	15.91B	1.79B	1.89B	0.82
MDT Medtronic Plc	86.27	111.27B	33.00B	4.29B	5.50B	2.71
EW Edwards Lifesciences Corp	72.07	42.66B	6.60B	4.16B	490.10M	2.34

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-16	Hochstufung	H.C. Wainwright	Neutral → Buy
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-08-28	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-08-08	Hochstufung	Piper Sandler	Neutral → Overweight
2023-08-04	Eingeleitet	SVB Securities	Outperform
2023-07-31	Hochstufung	Evercore ISI	Underperform → In-line
2023-06-07	Hochstufung	Wedbush	Underperform → Neutral
2023-05-16	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-17	Herabstufung	JP Morgan	Neutral → Underweight
2023-01-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-01-05	Bestätigt	H.C. Wainwright	Buy
2022-11-29	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-10-24	Herabstufung	Piper Sandler	Overweight → Neutral
2022-07-05	Herabstufung	Evercore ISI	In-line → Underperform
2022-05-16	Eingeleitet	H.C. Wainwright	Buy
2022-02-08	Eingeleitet	Loop Capital	Buy
2022-02-02	Hochstufung	Oppenheimer	Perform → Outperform
2022-01-20	Hochstufung	Truist	Hold → Buy
2022-01-03	Hochstufung	Evercore ISI	Underperform → In-line
2021-07-01	Herabstufung	Mizuho	Buy → Neutral
2021-04-14	Herabstufung	Wedbush	Neutral → Underperform
2021-01-25	Bestätigt	Piper Sandler	Overweight
2020-09-23	Eingeleitet	Northland Capital	Outperform
2020-09-18	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-09-17	Herabstufung	Truist	Buy → Hold
2020-06-01	Fortgesetzt	Oppenheimer	Perform
2020-05-01	Herabstufung	Oppenheimer	Outperform → Perform
2020-04-09	Herabstufung	Evercore ISI	In-line → Underperform
2020-03-05	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-01-02	Herabstufung	Evercore ISI	Outperform → In-line
2019-07-29	Hochstufung	SunTrust	Hold → Buy
2019-07-26	Herabstufung	JP Morgan	Overweight → Neutral
2019-07-26	Herabstufung	Wedbush	Outperform → Neutral
2019-03-20	Eingeleitet	SunTrust	Hold
2018-11-02	Herabstufung	Wells Fargo	Outperform → Market Perform
2018-07-16	Eingeleitet	Evercore ISI	Outperform
2018-04-18	Bestätigt	Mizuho	Buy
2018-02-23	Bestätigt	Mizuho	Buy
2017-05-24	Hochstufung	Wells Fargo	Market Perform → Outperform
2016-07-29	Bestätigt	Wedbush	Outperform
2016-01-19	Eingeleitet	Barclays	Underweight
2015-12-02	Eingeleitet	Deutsche Bank	Hold

Alle ansehen

Novocure Ltd Aktie (NVCR) Neueste Nachrichten

Nov 26, 2024

NVCR (NovoCure) Shares Outstanding (EOP) : 108.1 Mil (As of Sep. 2024) - GuruFocus.com

Nov 26, 2024

Nov 25, 2024

Novocure's SWOT analysis: FDA approval boosts cancer tech stock prospects - Investing.com

Nov 25, 2024

NovoCure (NASDAQ:NVCR) Receives Buy Rating from HC Wainwright - Defense World

Nov 25, 2024

Nov 24, 2024

NVCR (NovoCure) Growth Rank : 8 (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024

Nov 23, 2024

Connor Clark & Lunn Investment Management Ltd. Acquires 59,608 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Nov 23, 2024

Nov 22, 2024

FDA approves Novocure's new device for brain cancer treatment By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 21, 2024

Novocure secures FDA approval for add-ons to brain cancer treatment wearable - Yahoo Finance

Nov 21, 2024

Novocure’s HFE Transducer Arrays OK’ed with Optune Gio for Glioblastoma - MPO-mag

Nov 21, 2024

FDA approves Novocure's new device for brain cancer treatment - Investing.com

Nov 21, 2024

Novocure to Present Breakthrough TTFields Brain Cancer Treatment Data at SNO Meeting | NVCR Stock News - StockTitan

Nov 21, 2024

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma - Yahoo Finance

Nov 21, 2024

Nov 18, 2024

Can Novocure's PANOVA-3 Trial Of TTFields Therapy Electrify The Stock? - RTTNews

Nov 18, 2024

Nov 16, 2024

NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Nov 16, 2024

Nov 14, 2024

NovoCure (NVCR) Shares Cross Below 200 DMA - Nasdaq

Nov 14, 2024